These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. In vitro effects of two gold compounds, and D-penicillamine on the production of interferon gamma. Harth M; Cousin K; McCain GA Immunopharmacol Immunotoxicol; 1990; 12(1):39-60. PubMed ID: 2112569 [TBL] [Abstract][Full Text] [Related]
4. Synergistic inhibition of human B cell activation by gold sodium thiomalate and auranofin. Hirohata S; Nakanishi K; Yanagida T; Kawai M; Kikuchi H; Isshi K Clin Immunol; 1999 May; 91(2):226-33. PubMed ID: 10227815 [TBL] [Abstract][Full Text] [Related]
5. Synergistic inhibition of T cell proliferation by gold sodium thiomalate and auranofin. Hashimoto K; Whitehurst CE; Lipsky PE J Rheumatol; 1994 Jun; 21(6):1020-6. PubMed ID: 7932408 [TBL] [Abstract][Full Text] [Related]
6. The effect of antirheumatic drugs on interleukin 1 (IL-1) activity and IL-1 and IL-1 inhibitor production by human monocytes. Chang DM; Baptiste P; Schur PH J Rheumatol; 1990 Sep; 17(9):1148-57. PubMed ID: 1981242 [TBL] [Abstract][Full Text] [Related]
7. The effect of gold sodium thiomalate and auranofin on lipopolysaccharide-induced interleukin-1 production by blood monocytes in vitro: variation in healthy subjects and patients with arthritis. Danis VA; Kulesz AJ; Nelson DS; Brooks PM Clin Exp Immunol; 1990 Mar; 79(3):335-40. PubMed ID: 2107989 [TBL] [Abstract][Full Text] [Related]
8. An assay for the detection of interleukin-1 synthesis inhibitors: effects of antirheumatic drugs. Rordorf-Adam C; Lazdins J; Woods-Cook K; Alteri E; Henn R; Geiger T; Feige U; Towbin H; Erard F Drugs Exp Clin Res; 1989; 15(8):355-62. PubMed ID: 2513175 [TBL] [Abstract][Full Text] [Related]
9. Pivotal advance: inhibition of HMGB1 nuclear translocation as a mechanism for the anti-rheumatic effects of gold sodium thiomalate. Zetterström CK; Jiang W; Wähämaa H; Ostberg T; Aveberger AC; Schierbeck H; Lotze MT; Andersson U; Pisetsky DS; Erlandsson Harris H J Leukoc Biol; 2008 Jan; 83(1):31-8. PubMed ID: 17913975 [TBL] [Abstract][Full Text] [Related]
10. Effects of antirheumatic gold salts on cytokine-induced neutrophil-dependent cytotoxicity for human endothelial cells. Bratt J; Palmblad J J Investig Med; 2000 Nov; 48(6):395-402. PubMed ID: 11094861 [TBL] [Abstract][Full Text] [Related]
11. In vitro modulation of cytokine, cytokine inhibitor, and prostaglandin E release from blood mononuclear cells and synovial fibroblasts by antirheumatic drugs. Seitz M; Loetscher P; Dewald B; Towbin H; Baggiolini M J Rheumatol; 1997 Aug; 24(8):1471-6. PubMed ID: 9263137 [TBL] [Abstract][Full Text] [Related]
12. Effects of gold on cytokine production in vitro; increase of monocyte dependent interleukin 10 production and decrease of interferon-gamma levels. Lampa J; Klareskog L; Rönnelid J J Rheumatol; 2002 Jan; 29(1):21-8. PubMed ID: 11824965 [TBL] [Abstract][Full Text] [Related]
13. In vitro effects of 2 antirheumatic drugs on the synthesis and expression of proinflammatory cytokines in synovial membranes from patients with rheumatoid arthritis. Ounissi-Benkalha H; Pelletier JP; Tardif G; Mineau F; Jolicoeur FC; Ranger P; Martel-Pelletier J J Rheumatol; 1996 Jan; 23(1):16-23. PubMed ID: 8838503 [TBL] [Abstract][Full Text] [Related]
14. Toxicity of anti-rheumatic drugs in a randomized clinical trial of early rheumatoid arthritis. van Jaarsveld CH; Jahangier ZN; Jacobs JW; Blaauw AA; van Albada-Kuipers GA; ter Borg EJ; Brus HL; Schenk Y; van Der Veen MJ; Bijlsma JW Rheumatology (Oxford); 2000 Dec; 39(12):1374-82. PubMed ID: 11136881 [TBL] [Abstract][Full Text] [Related]
15. Clinical pharmacokinetics of slow-acting antirheumatic drugs. Tett SE Clin Pharmacokinet; 1993 Nov; 25(5):392-407. PubMed ID: 7904547 [TBL] [Abstract][Full Text] [Related]
16. Inhibition of cytokine activation processes in vitro by tenidap, a novel anti-inflammatory agent. McNiff PA; Laliberte RE; Svensson L; Pazoles CJ; Gabel CA Cytokine; 1995 Feb; 7(2):196-208. PubMed ID: 7780040 [TBL] [Abstract][Full Text] [Related]
17. KE-758, an active metabolite of the new anti-rheumatic drug KE-298, suppresses production of tumor necrosis factor-alpha and interleukin-1 beta in THP-1, a human monocyte cell line. Sugimoto M; Inoue T; Yamashita M; Takeshita K; Nakaike S Drugs Exp Clin Res; 2002; 28(5):197-205. PubMed ID: 12635495 [TBL] [Abstract][Full Text] [Related]
18. Correlation of in vitro and in vivo effects of gold compounds on leukocyte function: possible mechanisms of action. Wolach B; DeBoard JE; Coates TD; Baehner RL; Boxer LA J Lab Clin Med; 1982 Jul; 100(1):37-44. PubMed ID: 6283001 [TBL] [Abstract][Full Text] [Related]
19. Efficacy of sulphasalazine plus methotrexate in rheumatoid arthritis. Islam MN; Alam MN; Haq SA; Moyenuzzaman M; Patwary MI; Rahman MH Bangladesh Med Res Counc Bull; 2000 Apr; 26(1):1-7. PubMed ID: 11192489 [TBL] [Abstract][Full Text] [Related]
20. Effects of combinations of anti-rheumatic drugs on the production of vascular endothelial growth factor and basic fibroblast growth factor in cultured synoviocytes and patients with rheumatoid arthritis. Nagashima M; Wauke K; Hirano D; Ishigami S; Aono H; Takai M; Sasano M; Yoshino S Rheumatology (Oxford); 2000 Nov; 39(11):1255-62. PubMed ID: 11085806 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]